
Stoke Therapeutics, Inc.: shareholders and insiders
Price
$27.07
November 19, 2026Market cap $1.8B
What Ploutos Investor adds for Stoke Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- RTW Investments, LPwith 1 more personShare of class9.90%
- FMRwith 1 more personShare of class7.50%
- BlackRock, Inc.Share of class6.80%
- Redmile Group, LLCwith 2 more personsShare of class6.70%
- Lynx1 Capital Management LPwith 1 more personShare of class6.50%
- Morgan Stanleywith 1 more personShare of class6.50%
- Baker Bros. Advisors LPwith 3 more personsShare of class5.80%
- Biotechnology Value Fund L Pwith 9 more personsShare of class5.60%
- Wellington Management Group LLPwith 3 more personsShare of class5.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| RTW Investments, LPwith 1 more person | 9.90% | 5.94M | May 15, 20262 filings since Feb 14, 2025 | 13G/A | |
| FMRwith 1 more person | 7.50% | 4.82M | Nov 5, 20266 filings since Jun 6, 2025 | 13G/A | |
| BlackRock, Inc. | 6.80% | 3.73M | Oct 17, 20252 filings since Apr 16, 2025 | 13G/A | |
| Redmile Group, LLCwith 2 more persons | 6.70% | 4.16M | May 15, 20262 filings since Aug 14, 2025 | 13G/A | |
| Lynx1 Capital Management LPwith 1 more person | 6.50% | 4.04M | Aug 14, 20263 filings since May 15, 2026 | 13G/A | |
| Morgan Stanleywith 1 more person | 6.50% | 3.43M | Feb 3, 2025 | 13G/A | |
| Baker Bros. Advisors LPwith 3 more persons | 5.80% | 3.34M | Feb 17, 2026 | 13G/A | |
| Biotechnology Value Fund L Pwith 9 more persons | 5.60% | 3.61M | Sep 30, 2026 | 13G | |
| Wellington Management Group LLPwith 3 more persons | 5.20% | 3.10M | May 15, 2026 | 13G |
Fell to 5% or less (5)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+12%
- Millennium Mgmt (Englander)In the quarter+98%
- D.E. ShawIn the quarter+49%
- AQR CapitalIn the quarter-5.2%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 547.5K | +12% | $14M | 0.01% |
| Millennium Mgmt (Englander) | 515.8K | +98% | $13M | 0.01% |
| D.E. Shaw | 86.1K | +49% | $2.2M | 0.00% |
| AQR Capital | 25.1K | -5.2% | $700.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 15.7% of its shares outstanding were held short, -10.9% since the report before.
- Shares held short
- 10.26M
- 15.7%
- Since the report before11.51M on Sep 30, 2026
- -10.9%
- 12.3
- 831.8K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 96%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 4.31M
- Nov 15, 2023: Shares held short 4.08M
- Nov 30, 2023: Shares held short 4.02M
- Dec 15, 2023: Shares held short 3.19M
- Dec 29, 2023: Shares held short 3.32M
- Jan 12, 2024: Shares held short 3.44M
- Jan 31, 2024: Shares held short 4.13M
- Feb 15, 2024: Shares held short 3.97M
- Feb 29, 2024: Shares held short 3.76M
- Mar 15, 2024: Shares held short 3.55M
- Mar 28, 2024: Shares held short 4.95M
- Apr 15, 2024: Shares held short 5.53M
- Apr 30, 2024: Shares held short 8.31M
- May 15, 2024: Shares held short 7.91M
- May 31, 2024: Shares held short 8.22M
- Jun 14, 2024: Shares held short 8.36M
- Jun 28, 2024: Shares held short 9.47M
- Jul 15, 2024: Shares held short 10.30M
- Jul 31, 2024: Shares held short 9.82M
- Aug 15, 2024: Shares held short 9.89M
- Aug 30, 2024: Shares held short 9.25M
- Sep 13, 2024: Shares held short 8.71M
- Sep 30, 2024: Shares held short 6.98M
- Oct 15, 2024: Shares held short 6.79M
- Oct 31, 2024: Shares held short 6.70M
- Nov 15, 2024: Shares held short 6.40M
- Nov 29, 2024: Shares held short 6.73M
- Dec 13, 2024: Shares held short 7.26M
- Dec 31, 2024: Shares held short 7.48M
- Jan 15, 2025: Shares held short 8.75M
- Jan 31, 2025: Shares held short 8.99M
- Feb 14, 2025: Shares held short 10.09M
- Feb 28, 2025: Shares held short 11.17M
- Mar 14, 2025: Shares held short 11.71M
- Mar 31, 2025: Shares held short 12.09M
- Apr 15, 2025: Shares held short 12.56M
- Apr 30, 2025: Shares held short 12.84M
- May 15, 2025: Shares held short 11.67M
- May 30, 2025: Shares held short 12.03M
- Jun 13, 2025: Shares held short 12.11M
- Jun 30, 2025: Shares held short 11.53M
- Jul 15, 2025: Shares held short 11.50M
- Jul 31, 2025: Shares held short 11.43M
- Aug 15, 2025: Shares held short 11.19M
- Aug 29, 2025: Shares held short 10.74M
- Sep 15, 2025: Shares held short 11.39M
- Sep 30, 2025: Shares held short 10.78M
- Oct 15, 2025: Shares held short 10.83M
- Oct 31, 2025: Shares held short 10.67M
- Nov 14, 2025: Shares held short 11.25M
- Nov 28, 2025: Shares held short 10.56M
- Dec 15, 2025: Shares held short 9.31M
- Dec 31, 2025: Shares held short 10.72M
- Jan 15, 2026: Shares held short 11.15M
- Jan 30, 2026: Shares held short 11.18M
- Feb 13, 2026: Shares held short 11.80M
- Feb 27, 2026: Shares held short 12.40M
- Mar 13, 2026: Shares held short 13.38M
- Mar 31, 2026: Shares held short 12.82M
- Apr 15, 2026: Shares held short 12.54M
- Apr 30, 2026: Shares held short 13.03M
- May 15, 2026: Shares held short 12.92M
- May 29, 2026: Shares held short 11.23M
- Jun 15, 2026: Shares held short 11.72M
- Jun 30, 2026: Shares held short 13.91M
- Jul 15, 2026: Shares held short 15.69M
- Jul 31, 2026: Shares held short 15.81M
- Aug 14, 2026: Shares held short 12.98M
- Aug 31, 2026: Shares held short 11.20M
- Sep 15, 2026: Shares held short 11.15M
- Sep 30, 2026: Shares held short 11.51M
- Oct 15, 2026: Shares held short 10.26M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading61.0% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 61.0% of the shares in the reported trades were short sales, against 71.6% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 61.0%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 71.6%
- Change
- -10.6 pts
- Short sales a dayon average, of 421.4K shares
- 256.9K
- More than atof 3,656 US-listed companies, same days
- 85%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 79.8%
- Oct 13, 2026: Short sales 72.6%
- Oct 14, 2026: Short sales 87%
- Oct 15, 2026: Short sales 76.1%
- Oct 16, 2026: Short sales 73.2%
- Oct 19, 2026: Short sales 82.5%
- Oct 20, 2026: Short sales 76.7%
- Oct 21, 2026: Short sales 52.9%
- Oct 22, 2026: Short sales 80.3%
- Oct 23, 2026: Short sales 41.2%
- Oct 26, 2026: Short sales 72.4%
- Oct 27, 2026: Short sales 83%
- Oct 28, 2026: Short sales 77.8%
- Oct 29, 2026: Short sales 75%
- Oct 30, 2026: Short sales 63.6%
- Nov 2, 2026: Short sales 88.5%
- Nov 3, 2026: Short sales 57.8%
- Nov 4, 2026: Short sales 72.2%
- Nov 5, 2026: Short sales 57.1%
- Nov 6, 2026: Short sales 46.1%
- Nov 9, 2026: Short sales 53.5%
- Nov 10, 2026: Short sales 53.9%
- Nov 11, 2026: Short sales 30.8%
- Nov 12, 2026: Short sales 75%
- Nov 13, 2026: Short sales 75.5%
- Nov 16, 2026: Short sales 74.3%
- Nov 17, 2026: Short sales 65.3%
- Nov 18, 2026: Short sales 60.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.48%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.31%
- IBBiShares Biotechnology ETFWeight in the fund0.13%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.11%
- IWMiShares Russell 2000 ETFWeight in the fund0.06%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.05%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.04%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.04%
- VXFVanguard Extended Market Index FundWeight in the fund0.02%
- VHTVanguard Health Care Index FundWeight in the fund0.02%
17 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 151
- Q4 2025: Managers 184
- Q1 2026: Managers 199
- Q2 2026: Managers 198
Institutional investors by quarter
The fund managers holding STOK, quarter by quarter, from Q2 2019 to Q2 2025, 25 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 198 managers held 77.38M shares, worth $2.5B. During the quarter 31 opened a position, 32 closed one, 74 added and 57 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+9.1%
- Rtw InvestmentsIn the quarter
- FMRIn the quarter-1.3%
- Lynx1 Capital ManagementIn the quarter-15%
- Redmile GroupIn the quarter-5.2%
- Wellington Management GroupIn the quarter+14%
- Morgan StanleyIn the quarter+0.9%
- Baker Bros. AdvisorsIn the quarter
- Toronto Dominion BankIn the quarter
- State StreetIn the quarter+25%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 5.88M | +9.1% | $192M |
| Rtw Investments | 5.62M | $184M | |
| FMR | 5.31M | -1.3% | $174M |
| Lynx1 Capital Management | 4.04M | -15% | $132M |
| Redmile Group | 3.95M | -5.2% | $129M |
| Wellington Management Group | 3.52M | +14% | $115M |
| Morgan Stanley | 3.45M | +0.9% | $113M |
| Baker Bros. Advisors | 3.34M | $109M | |
| Toronto Dominion Bank | 3.17M | $104M | |
| State Street | 2.85M | +25% | $93M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Stoke Therapeutics's filings show?
Who buys and sells is one part of Stoke Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold STOK?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $14M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.